Children’s Hospital Medical Center, Cincinnati – Paraganglioma

Access Program Information

Currently there is no known effective treatment for patients with advanced stage
neuroblastoma, pheochromocytoma, or paraganglioma who have relapsed or not responded to
standard therapy. In previous studies that used 131I-MIBG as a potential anti-cancer
therapy, a decrease in the size of tumors was seen in some of the children and adults. This
research study will continue to evaluate the side effects of 131I-MIBG when treating
children and adults with neuroblastoma, pheochromocytoma, or paraganglioma. The 131I-MIBG
compound is intended to work by selectively delivering the radioactive iodine to the tumor
cells, which is then intended to result in their destruction.

The purpose of this research study is to:

– Make 131I-MIBG therapy available to patients with advanced neuroblastoma,
pheochromocytoma, or paraganglioma

– Further assess the side effects of 131I-MIBG therapy

Rare Disease: